Shares in Lilly, the company whose stock is expected to be most affected by its trial results, could lose 10% of their value if the company's compound doesn't meet all its study targets in October, estimates Mark Schoenebaum, an ISI Group pharmaceuticals and biotechnology analyst who gives solanezumab a 15% chance of success.

WSJ: For Alzheimer's, a Fork in the Road